
    
      Study design This is a multicenter, two arms, 2:1 (treatment: control) open-label randomized
      control study with a drug approved for another indication in Israel. All the patients
      enrolled will be treated with tocilizumab or not. One-month mortality rate is the primary
      endpoint. One arm will be the study drug anti-IL6R (Tocilizumab (Actmera)) 8 mg/kg given IV
      during one hour once. The placebo will be a 100 ml saline IV infusion administered along one
      hour.
    
  